Loading stock data…
MLAB
$109.03+0.57 (+0.53%)
After Hours$109.03+0.00 (+0.00%)· Last close Jun 9
Mesa Laboratories, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Mesa Laboratories, Inc. in the Technology sector is trading at $109.03. Wall Street consensus targets $112.00 (2 analysts), implying a +2.7% move over the next 12 months. The stock is currently near its 52-week high of $113.99, remaining 30.5% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
AAPLMSFTGOOGL
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$109.03
Potential Downside
0%
Whystock Fair Value$109.03
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Buy
Mean target$112.00+2.7%
Range$94.00 – $130.00
Fundamentals
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control seg...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.44%
ROE
Average efficiency. Growth may require heavy reinvestment.
5.81%
Volume
Today's trading volume
361,954
Recent News
3 Stocks Estimated To Be Trading 16.4% To 42% Below Intrinsic Value
In the last week, the United States market has stayed flat, yet it is up 26% over the past year with earnings forecast to grow by 17% annually. In such a robust market environment, identifying stocks trading below their intrinsic value can present unique opportunities for investors seeking potential growth.
Why Mesa Laboratories Stock Is Getting Hit With a Huge Sell-Off Today
Investors aren't happy with Mesa Labs latest quarterly report.
Undervalued Small Caps With Insider Buying Across Regions
The United States market has experienced a flat week, yet it has shown a robust 27% increase over the past year, with earnings anticipated to grow by 17% annually in the coming years. In this context of growth and stability, identifying stocks that are currently undervalued can offer potential opportunities for investors seeking to capitalize on insider confidence and regional strengths.
Undervalued Small Caps With Insider Buying Across Regions To Consider
Over the last 7 days, the United States market has risen by 4.0%, contributing to a remarkable 39% increase over the past year, with earnings projected to grow by 16% annually in the coming years. In this dynamic environment, identifying good stocks often involves looking for companies that are not only undervalued but also show signs of insider confidence, such as recent buying activity.
Here’s Why Conestoga Capital Advisors Sold Mesa Laboratories (MLAB)
Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2025 investor letter. As many believe, US equities experienced solid returns in 2025, with double-digit gains across all major indices, yet underlying conditions revealed extreme volatility and market leadership. A copy of the letter can be downloaded here. In Q4 2025, Conestoga Capital Advisors Small Cap Strategy […]